Allowing Companies

 
News Articles for Allowing Companies top ^
2013/5/7
Arrowhead Research Corporation (NASDAQ:ARWR) , a targeted therapeutics company, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Number 13/326,433 entitled, “Peptide-Based In Vivo siRNA Delivery System.” The allowed claims specifically protect the use of targeted melittin or melittin-like peptides to facilitate delivery of siRNA conjugates to hepatocytes.
Sign-up for Arrowhead Receives Patent Allowance for DPC siRNA Delivery System with Peptide Backbone investment picks
2013/3/7
BEDMINSTER, N.J., and DUBLIN, Ireland, March 7, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) , a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/614,111titled "Stable Pharmaceutical Compositions and Methods of Using the Same." This application includes claims intended to protect the proposed Vascepa ® (icosapent ethyl) indication based on Amarin's Phase 3 ANCHOR clinical trial results.
Sign-up for Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,111 Related to Vascepa(R) and Planned ANCHOR Indication investment picks
2013/2/1
Patent Application Related to High (≥200 mg/dL to <500 mg/dL) Triglyceride Patient Population With Mixed Dyslipidemia BEDMINSTER, N.J. and DUBLIN, Ireland, Feb.
Sign-up for Amarin Announces Notification of Additional U.S. Patent Allowance for U.S. Application 13/272,520 Based on ANCHOR Clinical Trial Results investment picks
2013/3/19
CRANBURY, N.J. , March 19, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/472,914 (the '914 application).  The application includes composition of matter claims on two of Palatin's most advanced melanocortin receptor-1 specific peptides.
Sign-up for Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides investment picks
2013/5/2
CRANBURY, N.J. , May 2, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 12/952,238 (the '238 application).  The application includes composition of matter claims on a new class of melanocortin receptor- specific peptides for sexual dysfunction and other indications.
Sign-up for Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction investment picks
2013/2/19
RHB-101 is a proprietary, controlled release, once-daily formulation of carvedilol for the treatment of hypertension, congestive heart failure and left ventricular dysfunction The expected expiration date of the US patent is 2024 TEL-AVIV, Israel, Feb.
Sign-up for RedHill Biopharma Announces Notice of Allowance From the United States Patent and Trademark Office for Its Cardio Drug RHB-101 investment picks
2013/1/31
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan.
Sign-up for Amarin Announces Notification of Two Additional Patent Allowances for U.S. Applications (13/458,496 and 13/349,157) Related to Vascepa(R) and FDA Approved MARINE Indication investment picks
2013/2/12
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb.
Sign-up for Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,129 Related to Vascepa(R) and FDA Approved MARINE Indication investment picks
2013/2/7
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb.
Sign-up for Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,146 Related to Vascepa(R) and FDA Approved MARINE Indication investment picks
2013/4/3
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today the receipt of a Notice of Claims Allowance for its U.S. Patent Application No.
Sign-up for Islet Sciences Receives Notice of Claims Allowance for U.S. Patent Application for New Medications for Treating Diabetes and other Serious Inflammatory Disorders investment picks
2013/3/6
Study reveals that other prominent real estate websites are missing up to 30% of homes for sale, and that over 15% of the homes they list as "for sale" are actually sold.
Sign-up for ZipRealty's New Listing Check Tool Allows Consumers to Verify if Homes They Find Online Are Really For Sale investment picks
2013/2/28
Arrowhead Research Corporation (NASDAQ: ARWR) , a targeted therapeutics company, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Number 13/336,028 entitled, “In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages.” This new IP expands the Dynamic Polyconjugate (DPC) platform, broadly protecting Arrowhead's next generation DPC polymer masking technology.
Sign-up for Arrowhead Receives Notice of Patent Allowance for New Protease Sensitive Masking Chemistry for DPC siRNA Delivery System investment picks
2013/1/31
Vuzix Receives Two New Notices of Patent Allowance for its Advanced Optics in Smart Glasses Canada NewsWire ROCHESTER, N.Y., Jan.
Sign-up for Vuzix Receives Two New Notices of Patent Allowance for its Advanced Optics in Smart Glasses investment picks
2013/3/28
Hudson Technologies, Inc. (NASDAQ: HDSN) , announced that the Environmental Protection Agency (EPA) issued its Final Rule on March 27 pertaining to allowances for virgin HCFC (R-22) for 2013 and 2014 and the previously noted recoupment allowances.
Sign-up for Hudson Technologies Reports the EPA’s Issuance of Final Rule on HCFC Allowances for 2013 and 2014 investment picks
2013/4/2
BUFFALO, N.Y., April 2, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) and Incuron, LLC, a joint venture between the Company and Bioprocess Capital Ventures, today announced the receipt of a Notice of Allowance from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for CBL0137.
Sign-up for Cleveland BioLabs and Incuron Announce Notice of Allowance From FDA to Commence Clinical Testing With CBL0137 investment picks
2013/4/5
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has received a Notice of Allowance from the U.S. Patent Trade Office (USPTO) on a patent application for the VIBEX™ QuickShot (QS) device, the latest advancement in its proprietary line of VIBEX™ auto-injector systems.
Sign-up for Antares Pharma Announces Notice of Allowance for New Patent on VIBEX™ QuickShot Device investment picks
2013/4/15
http://media.marketwire.com/attachments/201303/132813_FESLogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1006771&ProfileId=051205&sourceType=1 AKRON, OH --
Sign-up for FirstEnergy Solutions' New Online Tool Allows Businesses to Customize Fixed-Price Electricity Plans investment picks
2013/4/22
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of Biopump™, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced the United States Patent and Trademark Office has issued a Notice of Allowance of claims that expand the Company’s scope of patent coverage for additional therapeutic proteins.
Sign-up for Medgenics Receives Notice of Allowance from the U.S. Patent Office for Claims That Expand IP for Its Platform Technology to Additional Therapeutic Proteins investment picks
2013/5/2
http://media.marketwire.com/attachments/200704/325015_BellTel_resized_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1013389&ProfileId=051205&sourceType=1 TULSA, OK --
Sign-up for 53.2% Verizon Shareowners Vote "YES" on Proxy to Allow Long-Term Shareowners to Nominate Board Candidates investment picks
2013/3/6
Chase announced today that it is allowing homeowners affected by Hurricane Sandy to defer payments missed during the moratorium to the end of the loan term.
Sign-up for Chase Allows Sandy Homeowners to Defer Mortgage Payments Until End of Loan investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Allowing Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Allocation Stock Funds  |  Next: Allscripts Healthcare